6533b7cffe1ef96bd12597d8
RESEARCH PRODUCT
Clinical and genomic alternations predictive of response to sunitinib in patients with advanced renal cell carcinoma.
Theresa Margaret GoldOguz AkinSujata PatilJane HouldsworthBanumathy GowrishankarAndreas HoetkerAna M. MolinaChung-han LeeRobert J. MotzerManickam Janakiramansubject
OncologyCancer Researchmedicine.medical_specialtySunitinibbusiness.industryDiseaseurologic and male genital diseasesmedicine.diseaseClear cell renal cell carcinomaOncologyRenal cell carcinomaInternal medicinemedicineIn patientbusinessmedicine.drugdescription
e16109Background: Sunitinib is a 1st-line therapy for clear cell Renal Cell Carcinoma (ccRCC); however, 20-30% of tumors show primary resistant disease with progression as the best response. This s...
year | journal | country | edition | language |
---|---|---|---|---|
2016-05-20 | Journal of Clinical Oncology |